Duravelo-2 is Bicycle Therapeutics' trial of zelenectide pevedotin (BT8009) plus pembrolizumab as first-line treatment in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Bicycle designed it as a Phase 2/3 study and in 2026 converted it into a randomized Phase 2 trial. Zelenectide pevedotin is a Bicycle toxin conjugate — a Nectin-4-targeting bicyclic peptide linked to the cytotoxin monomethyl auristatin E (MMAE) via a cleavable linker. The drug targets the same antigen as enfortumab vedotin (Padcev) but as a small bicyclic peptide rather than an antibody-drug conjugate, giving it a different tissue-distribution and toxicity profile.
Bicycle confirmed the ASCO 2026 oral presentation slot in April 2026 (Abstract 4516, Monday June 1, 8:30-8:36 AM CT in the GU Cancers track). Interim data were released with the May 21 ASCO abstracts, and the June 1 rapid oral presentation (Abstract 4516, Yohann Loriot) reported that the optimal dose of zelenectide pevedotin plus pembrolizumab matched published standard-of-care response rates with roughly four-fold lower skin reactions and about half the peripheral neuropathy. In the earlier Duravelo-1 trial, zelenectide alone produced a 45% response rate (17 of 38) with an 11.1-month median duration of response in previously treated patients who had not received enfortumab vedotin (ESMO 2024), and zelenectide plus pembrolizumab produced a 65% rate (13 of 20 evaluable, 22 enrolled) in untreated cisplatin-ineligible patients (ASCO 2025).
Stories here cover Duravelo-2 interim data, the broader Bicycle Therapeutics Nectin-4 program (and the separate EphA2 conjugate nuzefatide pevedotin, BT5528), and the urothelial carcinoma treatment landscape. See #bicycle-therapeutics, #zelenectide-pevedotin, and #urothelial-cancer for adjacent threads.
In the June 1 rapid oral session (Abstract 4516, Yohann Loriot), the dose-optimization stage of the randomized Phase 2 Duravelo-2 trial showed the optimal dose of the bicyclic peptide-drug conjugate zelenectide pevedotin (BT8009) plus pembrolizumab produced response rates comparable to published standard-of-care data in previously untreated locally advanced or metastatic urothelial carcinoma, with roughly four-fold lower skin reactions and about half the peripheral neuropathy. The separate Duravelo-1 Phase 1 trial showed median progression-free survival comparable to standard of care in cisplatin-ineligible patients.
Bicycle Therapeutics' formal post-ASCO 2026 press release Friday morning specified the headline Phase 2 numbers from yesterday's abstract release. In the Duravelo-2 combination cohort, the optimal zelenectide dose plus pembrolizumab 200 mg every three weeks produced 65% ORR (17/26 evaluable patients) regardless of confirmation, with 58% BICR-confirmed ORR (15/26) at the 27-week cutoff in previously untreated locally advanced or metastatic urothelial cancer. An additional confirmed BICR response observed after the cutoff would bring the rate to 62%. The trial tested two dose schedules: 5 mg/m² weekly and 6 mg/m² two-weeks-on-one-week-off; the optimal dose moves forward. Treatment retention was high and dose-limiting adverse events limited. The 65% ORR is similar to the 65% (13/20) seen with the same combination in untreated cisplatin-ineligible patients in the earlier Duravelo-1 trial, though comparisons across trials are limited.
Bicycle Therapeutics released Duravelo-2 Phase 2 interim analysis data at ASCO 2026 — zelenectide pevedotin (BT8009, a Nectin-4-targeting bicyclic peptide-MMAE conjugate) plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer. The full data presentation is scheduled for Monday June 1, 8:30-8:36 AM CT in the GU Cancers oral session (Abstract 4516). In the earlier Duravelo-1 trial, zelenectide plus pembrolizumab produced a 65% response rate (13 of 20 evaluable patients) in untreated cisplatin-ineligible patients (ASCO 2025). Bicycle's five ASCO abstracts, all on zelenectide, pair the Duravelo-2 oral with four posters: Duravelo-2 in previously treated patients, two Duravelo-1 updates, and a dose-optimization analysis.
Bicycle Therapeutics confirmed the Duravelo-2 oral abstract presentation slot at the ASCO 2026 Annual Meeting on Monday, June 1, 8:30–8:36 a.m. CT. The abstract reports interim analysis results from Duravelo-2, a randomized Phase 2 trial of zelenectide pevedotin (BT8009) plus pembrolizumab as first-line treatment for previously untreated locally advanced or metastatic urothelial carcinoma. Zelenectide pevedotin is Bicycle's Nectin-4-targeting bicyclic peptide-drug conjugate, a separate program from the EphA2-targeting nuzefatide pevedotin (BT5528) covered earlier on this site. Bicycle's April 30 first-quarter report listed $559.5M in cash and a runway into 2030.
Bicycle Therapeutics reported a first-quarter net loss of $60.8M ($0.87 per share) on April 30, with R&D expenses of $48.9M and $559.5M in cash and equivalents at March 31, which it expects to fund operations into 2030. After a first-quarter reprioritization, Bicycle is converting Duravelo-2, its trial of zelenectide pevedotin (BT8009) plus pembrolizumab in metastatic urothelial cancer, into a randomized Phase 2 trial, with initial dose-selection data set for ASCO 2026. It is shifting resources to nuzefatide pevedotin (BT5528), whose Phase 2 trial in recurrent pancreatic cancer dosed its first patient in April, and to radiopharmaceuticals and imaging agents.
Bicycle Therapeutics will present five abstracts at the 2026 ASCO Annual Meeting (May 29-June 2 in Chicago), all on zelenectide pevedotin (BT8009), its Nectin-4-targeting bicyclic peptide-drug conjugate. Yohann Loriot will give interim Duravelo-2 results with pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer in a June 1 rapid oral session (Abstract 4516). Four May 31 posters cover Duravelo-2 in previously treated patients, two Duravelo-1 updates, and dose optimization.